DUBLIN–(BUSINESS WIRE)–The “Uveitis – Global Drug Forecast and Market Analysis to 2029” report has been added to ResearchAndMarkets.com’s offering.
Uveitis affecting the anterior chamber is typically treated with corticosteroid eye drops such as Allergan’s Pred Forte (prednisolone acetate) or Novartis’ Maxidex (dexamethasone). Inflammation that involves other parts of the uveal tract can be treated with injectable corticosteroids such as Novartis’ Triesence (triamcinolone acetonide) or ocular implants such as Allergan’s Ozurdex (dexamethasone).
When the disease is caused by an autoimmune disorder, immunomodulators such as methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine can be used to manage patients.
AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab) are monoclonal antibodies that are injected periodically to manage uveitis that is associated with indications such as rheumatoid arthritis and ulcerative colitis.
The publisher projects the global non-infectious uveitis marketplace-which, for the purposes of this report, comprises the nine major pharmaceutical markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Canada, and Australia)-to experience modest growth during the forecast period. The non-infectious uveitis market was valued at $286.3M in 2019.
Growth in the market will be driven by the highly anticipated arrivals of intraocular drugs including an anti-inflammatory gene therapy, and a complement inhibitor. In 2029, the market is projected to reach $789.7M. The non-infectious uveitis market will expand at a Compound Annual Growth Rate (CAGR) of 10.7%.
Key Highlights
- Drugs for non-infectious uveitis generated an estimated $286.3M in 2019, across the 9MM. The publisher projects that the market will expand at a Compound Annual Growth Rate (CAGR) of 10.7%, reaching $789.7M in 2029.
- Corticosteroids and immunosuppressants such as methotrexate, azathioprine, and tacrolimus are frequently used to treat patients with uveitis. The main issue with corticosteroids is their potential to cause elevated intraocular pressures and cataracts. Most patients develop these complications after long-term treatment with steroids.
- Immunosuppressants such as azathioprine and tacrolimus take several weeks to bring about therapeutic outcomes. Humira (adalimumab) was the first biologic to gain approval for the treatment of uveitis. However, the drug is injected subcutaneously, and this has been linked to dermatological side effects and discomfort.
- Anterior uveitis makes up the majority of diagnosed prevalent cases of the disease. However, symptoms can overlap with conjunctivitis and keratitis. This can lead to misdiagnosis and delayed initiation of effective treatment.
- A number of drugs that are being developed for uveitis are also in the pipeline for other inflammatory diseases. This is useful because a significant percentage of patients with non-infectious uveitis also have an immune system-related comorbidity.
- Factors that will contribute to growth in the market include continued use of AbbVie’s Humira for the treatment of both anterior and posterior uveitis, the introduction of non-steroidal therapies for the management of patients with anterior uveitis, and the assumed increase in the number of people who develop recurrent uveitis in line with the growing prevalence of autoimmune conditions.
- Barriers to growth include the use of inexpensive generic formulations of immunosuppressants in all of the 9MM and lack of compliance among patients who are instructed to apply eye drops up to six times per day.
- The top-selling late-stage pipeline agent in 2029 will be EYS-606. This is because the drug is expected to be the only gene therapy that will become available to treat anterior uveitis during the forecast window.
Key Topics Covered:
1 Uveitis: Executive Summary
1.1 The Uveitis Market Will Almost Triple In Size from 2019-2029
1.2 Steroid-Sparing Immunosuppressive Strategies Increasingly Favored by Clinicians and Patients
1.3 Lack of Novel Therapies for Anterior Uveitis Will Limit Market Growth in Japan, Canada, and Australia
1.4 Strategic Alliances Are a Key Priority for Drug Developers in This Therapy Area
1.5 Focus Is On Label Expansion and Treatment of Comorbidities in the Uveitis Pipeline
1.6 What Do Physicians Think?
2 Introduction
3 Disease Overview
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 9MM Forecast Methodology
4.5 Epidemiological Forecast for Uveitis
4.6 Discussion
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 Treatment Guidelines
5.3 Pharmacotherapeutic Management of Non-infectious Uveitis
5.3.1 Anterior Uveitis
5.3.2 Intermediate, Posterior, and Panuveitis
5.4 Marketed Drugs by Therapeutic Class
5.4.1 Corticosteroids
5.4.2 Immunosuppressants
5.4.3 Antimuscarinic Agents
5.5 Treatment of Uveitis by Geographic Region
5.5.1 North America
5.5.2 5EU
5.5.3 Asia-Pacific
5.6 KOL Insights on Disease Management
6 Competitive Assessment
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Increasing Disease Awareness Among Physicians and Patients
7.3 Improving the Safety and Side-Effect Profiles of Pharmaceutical Products
7.4 Making Drug Administration More Manageable for Patients
7.5 Standardization of Treatment Guidelines for Different Disease Subtypes
8 R&D Strategies
8.1 Overview
8.1.1 Innovation in the Uveitis Pipeline
8.1.2 Repurposing Biologic Therapies Marketed for Autoimmune Diseases
8.1.3 Optimizing Administration of Immunosuppressants
8.2 Clinical Trials Design
8.2.1 Primary and Secondary Endpoints
8.2.2 Trial Duration and Steroid-Sparing Treatment Strategies
8.2.3 Uveitis as an Add-On Indication
9 Pipeline Assessment
9.1 Overview
9.2 Clinical Trials
9.3 Late-Stage Pipeline Products
9.4 Other Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Clinical Benchmarking
10.3 Commercial Benchmarking
10.4 Competitive Assessment
11 Current and Future Players
11.1 Overview
11.2 Trends in Corporate Strategy
11.3 Deal-Making Trends
11.4 Analysis of Company Portfolios in the Uveitis Market
11.4.1 AbbVie and Allergan
11.4.2 Novartis/Alcon
11.5 Analysis of Company Portfolios in the Uveitis Pipeline
11.5.1 Chugai
11.5.2 Aciont
11.5.3 Oculis
11.5.4 Tarsius Pharma
11.5.5 Enzo Biochem
11.5.6 Santen
11.5.7 Eyevensys
11.5.8 Panoptes Pharma
12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers – Global Issues
13 Appendix
Companies Mentioned
- Apothecon
- Novartis
- Wakamoto
- Allergan
- Johnson & Johnson
- Bausch & Lomb
- EyePoint Pharmaceuticals
- Alimera
- Pfizer
- Intrapharm
- Baxter Healthcare
- Shionogi
- Astellas
- Janssen
- AbbVie
- Merck
- Roche
- Genentech
- Mitsubishi Tanabe Pharma
- Chugai
- Santen
- Aciont
- Eyevensys
- Oculis
- Enzo Biochem
- Panoptes Pharma
- Tarsius Pharma
- Alvotech
- Dobecure
- Mitotech
- Sun Pharma
- EyeGate Pharma
- Amgen
- Affibody
- Revolo Biotherapeutics
- Apitope International
- Palatin Technologies
- Reven Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/wenehh
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900